Inspire Medical Systems, Inc. (NYSE: INSP)

$42.62 ▲ +0.70 (+1.67%)

As of May 14, 2026 03:59 PM

Sector: Healthcare Industry: Medical Devices CIK: 0001609550

Market Cap 1.20 Bn

P/E 9.40

P/S 1.31

Div. Yield 0.00

ROIC (Qtr) 0.00

Revenue Growth (1y) (Qtr) 1.62

Add ratio to table...

About

Inspire Medical Systems Inc is a medical technology company that develops and commercializes innovative minimally invasive solutions for patients with obstructive sleep apnea. Its flagship product the Inspire system is the first neurostimulation therapy to receive FDA approval European Union MDR approval and Japan approval for treating moderate to severe obstructive sleep apnea. The Inspire system uses a closed loop algorithm that senses breathing and delivers mild hypoglossal nerve stimulation to keep the airway open during sleep. More than 125000...

Inspire Medical Systems Inc is a medical technology company that develops and commercializes innovative minimally invasive solutions for patients with obstructive sleep apnea. Its flagship product the Inspire system is the first neurostimulation therapy to receive FDA approval European Union MDR approval and Japan approval for treating moderate to severe obstructive sleep apnea. The Inspire system uses a closed loop algorithm that senses breathing and delivers mild hypoglossal nerve stimulation to keep the airway open during sleep. More than 125000 patients have received Inspire therapy in the United States Europe and Asia since its launch. The device obtained premarket approval from the FDA in 2014 a CE mark in Europe in 2010 and regulatory clearance in Japan in 2018.

Inspire Medical Systems generates revenue primarily by selling the Inspire system to hospitals and ambulatory surgery centers. In the United States and select European markets the company uses a direct sales force to call on ENT physicians and sleep centers. In Japan and Singapore Inspire therapy is sold through independent distributors. Revenue also comes from related services such as patient support programs prior authorization assistance and the SleepSync cloud based platform. Hospitals and ambulatory surgery centers bill third party payors including commercial insurers Medicare and Medicaid for the procedure and device costs.

• no_segments_reported.

Inspire Medical Systems holds a first mover advantage in the neurostimulation space for obstructive sleep apnea. It is the only company with an FDA approved closed loop system that senses respiration and delivers timed hypoglossal nerve stimulation. Competitors include Nyxoah which offers an open loop bilateral stimulation device and LivaNova which has submitted a hypoglossal nerve stimulation device for FDA review. Traditional continuous positive airway pressure providers such as ResMed Philips and Fisher & Paykel remain the first line therapy but face compliance challenges. Invasive surgical options like uvulopalatopharyngoplasty and maxillomandibular advancement serve as alternative second line treatments. Inspire differentiates itself through a robust body of clinical evidence including over 385 peer reviewed publications long term data from the STAR trial and real world results from the ADHERE registry. The company also benefits from a strong intellectual property portfolio with 119 issued US patents 83 issued foreign patents and numerous pending applications. Its market access team helps secure prior authorizations and coverage policies with commercial payors and Medicare facilitating reimbursement for patients and providers. Direct to consumer marketing and patient education programs further drive demand and brand awareness.

Inspire Medical Systems serves hospitals and ambulatory surgery centers that perform the implantation procedure. These customers are located throughout the United States in selected European countries and in Japan and Singapore through distributor partners. The company also works closely with ENT physicians sleep centers and referral sources who identify appropriate patients for Inspire therapy. While specific customer names are not disclosed the base includes academic medical centers community hospitals and independent surgery centers. Patients who have failed or cannot tolerate continuous positive airway pressure therapy represent the target end user group for the Inspire system.

Investment thesis

Bull case

The company’s recent clarification that the Inspire 5 procedure will be billed under CPT code 64582 with a –52 modifier introduces a significant opportunity to preserve revenue, even if the initial reimbursement reduction ranges up to 50%. Management’s repeated emphasis on a “smaller reduction” based on surgical skill and the 10,000 procedures performed in 2025 signals that the industry is leaning toward a 10–20 % adjustment rather than the lower bound of the range. If this outcome materializes, the company’s revised 2026 revenue guidance of $950 million to $1 billion would translate into operating margins of 6–8 %, comfortably above the industry average for medical‑device specialists. Moreover, the early data from the Singapore study and the limited U.S. launch demonstrate a 79.5 % responder rate using the Sher criteria—well above the 66 % rate reported in the original STAR Phase III pivotal trial—bolstering the case that Inspire 5 offers a superior clinical profile that can drive patient demand and justify premium pricing. These strong clinical outcomes, coupled with the company’s high implant rate (90 % of centers are currently deploying Inspire 5), create a durable pipeline that can absorb any short‑term reimbursement turbulence. In addition, the firm’s proactive engagement with physicians, societies, and payers—evidenced by the nearly 95 % completion of contracting for centers—will help standardize coding practices and reduce claim denials. Finally, the company’s robust cash position ($405 million at year‑end 2025) and $50 million share repurchase program demonstrate financial discipline and an ability to fund growth initiatives or absorb unforeseen costs, providing a buffer that further supports long‑term value creation.
The introduction of the Inspire 6 platform in 2026, featuring sleep‑detection and auto‑activation capabilities, signals a clear product roadmap that positions the company ahead of competitors in the rapidly evolving field of closed‑loop therapy. By automating device activation when a patient falls asleep, Inspire 6 is expected to enhance adherence, a critical determinant of long‑term efficacy and repeat device utilization. The company’s claim that this new iteration will “maximize therapy adherence” suggests that the market can anticipate incremental revenue from both new implantations and potential upgrades, effectively extending the life cycle of the existing Inspire 5 user base. This product differentiation also dovetails with emerging digital health trends, as the firm continues to invest in SleepSync’s prior‑authorization feature, thereby simplifying the reimbursement workflow and reinforcing the ecosystem’s attractiveness to payers and providers alike. Such vertical integration, combining device innovation with digital workflow optimization, is likely to yield a higher value proposition that can command favorable pricing and secure a sustainable competitive moat.
The company’s clinical and operational achievements in 2025—particularly the $269 million fourth‑quarter revenue and $912 million full‑year top line—were driven by a higher mix of Inspire 5 implants and efficient cost management, resulting in improved operating margin. The management’s commentary that operating cash flow of $52 million in Q4, and $117 million for the year, underpins the firm’s capacity to support capital expenditures of $45–$50 million for 2026 while simultaneously executing a $175 million repurchase program. Such disciplined capital allocation reflects an ability to maintain profitability while investing in the next‑generation product pipeline and in patient‑centered digital tools, thereby positioning the company for sustainable long‑term growth. The firm’s focus on training advanced practice providers and certifying additional surgeons further strengthens its sales force, ensuring that the product is widely available across high‑volume centers and expanding its reach to new markets. The cumulative effect of these initiatives is a robust operating model that can absorb short‑term reimbursement volatility and maintain momentum in the competitive OSA device market.
Despite the company’s dominant U.S. presence (95 % of revenue), its strategic positioning in the global market offers a significant growth lever. The firm’s 4–5 % contribution from overseas markets in 2026, while modest, indicates a baseline presence that can be amplified as the company leverages its strong clinical data and reimbursement success in the United States to enter new jurisdictions. As the company expands its regulatory approvals, including recent FDA clearance for 3 Tesla MRI compatibility, it can tap into the growing demand for MRI‑compatible OSA devices, especially in countries with high MRI utilization rates. This expansion, coupled with the existing pipeline of Inspire 6, provides a clear path to capture international market share and diversify revenue streams away from the highly regulated U.S. market. The company’s proven ability to navigate complex payer landscapes and its experience in launching new devices quickly further support its expansion prospects.
The growing trend of GLP‑1 therapies for weight management presents a unique tailwind for the company’s OSA market. The management’s acknowledgment that GLP‑1 agents can reduce body weight and thereby lower apnea severity signals that patients already seeking weight‑loss therapies may simultaneously become candidates for Inspire therapy. By proactively partnering with weight‑loss programs and leveraging data from the Singapore study, the company can position itself as a complementary solution to GLP‑1 therapies, thereby widening the patient pool. This strategic synergy also enables cross‑selling opportunities and may reduce the patient acquisition cost, as patients already engaged with weight‑loss providers are more likely to consider a non‑CPAP solution. Thus, the company’s forward‑looking view on GLP‑1s offers a credible, albeit indirect, revenue driver that can mitigate some of the risks inherent in the OSA device market.

The company’s recent clarification that the Inspire 5 procedure will be billed under CPT code 64582 with a –52 modifier introduces a significant opportunity to preserve revenue, even if the initial reimbursement reduction ranges up to 50%. Management’s repeated emphasis on a “smaller reduction” based on surgical skill and the 10,000 procedures performed in 2025 signals that the industry is leaning toward a 10–20 % adjustment rather than the lower bound of the range. If this outcome materializes, the company’s revised 2026 revenue guidance of $950 million to $1 billion would translate into operating margins of 6–8 %, comfortably above the industry average for medical‑device specialists. Moreover, the early data from the Singapore study and the limited U.S. launch demonstrate a 79.5 % responder rate using the Sher criteria—well above the 66 % rate reported in the original STAR Phase III pivotal trial—bolstering the case that Inspire 5 offers a superior clinical profile that can drive patient demand and justify premium pricing. These strong clinical outcomes, coupled with the company’s high implant rate (90 % of centers are currently deploying Inspire 5), create a durable pipeline that can absorb any short‑term reimbursement turbulence. In addition, the firm’s proactive engagement with physicians, societies, and payers—evidenced by the nearly 95 % completion of contracting for centers—will help standardize coding practices and reduce claim denials. Finally, the company’s robust cash position ($405 million at year‑end 2025) and $50 million share repurchase program demonstrate financial discipline and an ability to fund growth initiatives or absorb unforeseen costs, providing a buffer that further supports long‑term value creation.
The introduction of the Inspire 6 platform in 2026, featuring sleep‑detection and auto‑activation capabilities, signals a clear product roadmap that positions the company ahead of competitors in the rapidly evolving field of closed‑loop therapy. By automating device activation when a patient falls asleep, Inspire 6 is expected to enhance adherence, a critical determinant of long‑term efficacy and repeat device utilization. The company’s claim that this new iteration will “maximize therapy adherence” suggests that the market can anticipate incremental revenue from both new implantations and potential upgrades, effectively extending the life cycle of the existing Inspire 5 user base. This product differentiation also dovetails with emerging digital health trends, as the firm continues to invest in SleepSync’s prior‑authorization feature, thereby simplifying the reimbursement workflow and reinforcing the ecosystem’s attractiveness to payers and providers alike. Such vertical integration, combining device innovation with digital workflow optimization, is likely to yield a higher value proposition that can command favorable pricing and secure a sustainable competitive moat.
The company’s clinical and operational achievements in 2025—particularly the $269 million fourth‑quarter revenue and $912 million full‑year top line—were driven by a higher mix of Inspire 5 implants and efficient cost management, resulting in improved operating margin. The management’s commentary that operating cash flow of $52 million in Q4, and $117 million for the year, underpins the firm’s capacity to support capital expenditures of $45–$50 million for 2026 while simultaneously executing a $175 million repurchase program. Such disciplined capital allocation reflects an ability to maintain profitability while investing in the next‑generation product pipeline and in patient‑centered digital tools, thereby positioning the company for sustainable long‑term growth. The firm’s focus on training advanced practice providers and certifying additional surgeons further strengthens its sales force, ensuring that the product is widely available across high‑volume centers and expanding its reach to new markets. The cumulative effect of these initiatives is a robust operating model that can absorb short‑term reimbursement volatility and maintain momentum in the competitive OSA device market.
Despite the company’s dominant U.S. presence (95 % of revenue), its strategic positioning in the global market offers a significant growth lever. The firm’s 4–5 % contribution from overseas markets in 2026, while modest, indicates a baseline presence that can be amplified as the company leverages its strong clinical data and reimbursement success in the United States to enter new jurisdictions. As the company expands its regulatory approvals, including recent FDA clearance for 3 Tesla MRI compatibility, it can tap into the growing demand for MRI‑compatible OSA devices, especially in countries with high MRI utilization rates. This expansion, coupled with the existing pipeline of Inspire 6, provides a clear path to capture international market share and diversify revenue streams away from the highly regulated U.S. market. The company’s proven ability to navigate complex payer landscapes and its experience in launching new devices quickly further support its expansion prospects.
The growing trend of GLP‑1 therapies for weight management presents a unique tailwind for the company’s OSA market. The management’s acknowledgment that GLP‑1 agents can reduce body weight and thereby lower apnea severity signals that patients already seeking weight‑loss therapies may simultaneously become candidates for Inspire therapy. By proactively partnering with weight‑loss programs and leveraging data from the Singapore study, the company can position itself as a complementary solution to GLP‑1 therapies, thereby widening the patient pool. This strategic synergy also enables cross‑selling opportunities and may reduce the patient acquisition cost, as patients already engaged with weight‑loss providers are more likely to consider a non‑CPAP solution. Thus, the company’s forward‑looking view on GLP‑1s offers a credible, albeit indirect, revenue driver that can mitigate some of the risks inherent in the OSA device market.

Bear case

The most significant risk stems from the unresolved coding and reimbursement landscape for Inspire 5. While management asserts a “smaller reduction” is likely, the current guidance range (10 % to 50 % professional fee cut) reflects a substantial uncertainty that could compress margins by 6–8 % or more if the lower bound materializes. This ambiguity directly translates into a revenue range of $950 million to $1 billion for 2026, meaning the company’s operating earnings could swing by $60–70 million depending on the outcome. Moreover, the company’s heavy reliance on private‑practice surgeons—who receive compensation largely from professional fees—means that a 50 % cut could significantly dampen physician willingness to perform the procedure, constraining market penetration and undermining the projected growth in implant volume. The CFO’s remarks that the exact reduction will not be known until sufficient claims data are available further expose the company to a prolonged period of uncertainty that may erode investor confidence.
The WISER program—designed to reduce inappropriate use of Inspire therapy—has already introduced denials and administrative burden in six pilot states, as noted by management. The company’s admission that “many Medicare cases have been submitted and approved, but there have also been denials” suggests that a meaningful portion of early‑market volume is being delayed or lost. These denials may not only reduce immediate revenue but also erode relationships with key payer networks, potentially jeopardizing future contracting. The firm’s limited description of corrective actions, aside from providing prior‑authorization support, signals that the underlying systemic issues may persist, especially as the program expands beyond the pilot states. Consequently, the WISER program presents a tangible, near‑term threat to revenue growth that management has not fully quantified.
Competitive pressure from emerging players such as Nyxoah, which recently reported its Q4 results, introduces uncertainty about the firm’s market share trajectory. The management’s brief reference to competition—“We have built a little impact into our guide” and “we are still confident that we are in a very strong position”—is evasive, offering no concrete differentiation or pricing strategy. If competitors achieve similar or better clinical outcomes, or if they secure more favorable reimbursement coding, they could siphon high‑volume centers away from Inspire, especially in markets where reimbursement rates are already under pressure. The lack of clear data on the relative performance of competitor devices, combined with the company’s heavy dependence on a single product line, amplifies the risk that market dynamics could shift in favor of alternatives, eroding the firm’s growth prospects.
The company’s dependence on a high inventory of Inspire 4 units, slated to be phased out in 2026, poses a potential stranded‑asset risk. Management noted that “inventory is sufficient for centers that may choose to remain with Inspire 4 for the foreseeable future,” yet the company’s own statements that it “does not believe centers in the U.S. will really go back to Inspire 4” imply a misalignment between inventory management and market demand. If the transition to Inspire 5 stalls—whether due to reimbursement uncertainty or regulatory delays—the company could face obsolescence costs for components and assembly lines tied to the older product. Such inventory write‑downs would not only impact the balance sheet but could also lead to cash‑flow deficits as capital is tied up in slow‑moving stock.
Reimbursement risk extends beyond the –52 modifier to the broader process of obtaining a new category I CPT code, which is projected to be approved only in 2028. This three‑year lag means the company will continue to operate under a provisional code that may not reflect the true value of the procedure, thereby exposing the firm to prolonged payment volatility. Management’s statement that “the new CPT code will be approved in 2028” underscores the long‑term uncertainty, while the “dual‑track” strategy—working on a smaller reduction under the current code while pursuing a new code—creates operational complexity and may dilute focus. The risk that the new code could be approved with a lower reimbursement or that payers may resist the change further compounds the uncertainty in revenue forecasting.

The most significant risk stems from the unresolved coding and reimbursement landscape for Inspire 5. While management asserts a “smaller reduction” is likely, the current guidance range (10 % to 50 % professional fee cut) reflects a substantial uncertainty that could compress margins by 6–8 % or more if the lower bound materializes. This ambiguity directly translates into a revenue range of $950 million to $1 billion for 2026, meaning the company’s operating earnings could swing by $60–70 million depending on the outcome. Moreover, the company’s heavy reliance on private‑practice surgeons—who receive compensation largely from professional fees—means that a 50 % cut could significantly dampen physician willingness to perform the procedure, constraining market penetration and undermining the projected growth in implant volume. The CFO’s remarks that the exact reduction will not be known until sufficient claims data are available further expose the company to a prolonged period of uncertainty that may erode investor confidence.
The WISER program—designed to reduce inappropriate use of Inspire therapy—has already introduced denials and administrative burden in six pilot states, as noted by management. The company’s admission that “many Medicare cases have been submitted and approved, but there have also been denials” suggests that a meaningful portion of early‑market volume is being delayed or lost. These denials may not only reduce immediate revenue but also erode relationships with key payer networks, potentially jeopardizing future contracting. The firm’s limited description of corrective actions, aside from providing prior‑authorization support, signals that the underlying systemic issues may persist, especially as the program expands beyond the pilot states. Consequently, the WISER program presents a tangible, near‑term threat to revenue growth that management has not fully quantified.
Competitive pressure from emerging players such as Nyxoah, which recently reported its Q4 results, introduces uncertainty about the firm’s market share trajectory. The management’s brief reference to competition—“We have built a little impact into our guide” and “we are still confident that we are in a very strong position”—is evasive, offering no concrete differentiation or pricing strategy. If competitors achieve similar or better clinical outcomes, or if they secure more favorable reimbursement coding, they could siphon high‑volume centers away from Inspire, especially in markets where reimbursement rates are already under pressure. The lack of clear data on the relative performance of competitor devices, combined with the company’s heavy dependence on a single product line, amplifies the risk that market dynamics could shift in favor of alternatives, eroding the firm’s growth prospects.
The company’s dependence on a high inventory of Inspire 4 units, slated to be phased out in 2026, poses a potential stranded‑asset risk. Management noted that “inventory is sufficient for centers that may choose to remain with Inspire 4 for the foreseeable future,” yet the company’s own statements that it “does not believe centers in the U.S. will really go back to Inspire 4” imply a misalignment between inventory management and market demand. If the transition to Inspire 5 stalls—whether due to reimbursement uncertainty or regulatory delays—the company could face obsolescence costs for components and assembly lines tied to the older product. Such inventory write‑downs would not only impact the balance sheet but could also lead to cash‑flow deficits as capital is tied up in slow‑moving stock.
Reimbursement risk extends beyond the –52 modifier to the broader process of obtaining a new category I CPT code, which is projected to be approved only in 2028. This three‑year lag means the company will continue to operate under a provisional code that may not reflect the true value of the procedure, thereby exposing the firm to prolonged payment volatility. Management’s statement that “the new CPT code will be approved in 2028” underscores the long‑term uncertainty, while the “dual‑track” strategy—working on a smaller reduction under the current code while pursuing a new code—creates operational complexity and may dilute focus. The risk that the new code could be approved with a lower reimbursement or that payers may resist the change further compounds the uncertainty in revenue forecasting.

Segments Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	145.93 Bn	23.33	3.23	34.05 Bn
2	SYK	Stryker Corp	115.71 Bn	34.62	4.58	14.72 Bn
3	MDT	Medtronic plc	97.69 Bn	21.17	2.75	28.07 Bn
4	BSX	Boston Scientific Corp	78.71 Bn	22.00	3.82	11.03 Bn
5	EW	Edwards Lifesciences Corp	47.63 Bn	44.75	7.85	0.60 Bn
6	PHG	Koninklijke Philips Nv	29.38 Bn	13,009.40	1.46	8.07 Bn
7	DXCM	Dexcom Inc	22.72 Bn	24.58	4.72	-
8	STE	STERIS plc	20.71 Bn	29.06	3.55	1.90 Bn

Research Tools

Inspire Medical Systems, Inc. (NYSE: INSP)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password